English Swedish
Published: 2023-02-22 07:30:00 CET
Surgical Science Sweden AB
Interim information

Year-end report 2022: STRONG END TO AN AMAZING YEAR

FOURTH QUARTER 2022 (OCT – DEC)

Net sales amounted to SEK 250.1 million (197.7), corresponding to an increase of 27 percent compared with the corresponding period in the preceding year. The preceding year's figure included an item of SEK 9.5 million attributable to the adjustment of accounting principles regarding the period in which certain income is reported. Adjusted for this item, sales increased by 33 percent.

Operating profit amounted to SEK 61.2 million (44.5).

Net profit amounted to SEK 116.5 million (66.9), corresponding to earnings per share of SEK 2.29 (1.32).

Cash flow from operating activities amounted to an inflow of SEK 78.5 million (outflow 13.0). As of December 31, 2022, cash and cash equivalents amounted to SEK 433.7 million (316.7).

FULL-YEAR 2022

Net sales amounted to SEK 802.5 million (366.8), corresponding to an increase of 119 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 34 percent.

Operating profit amounted to SEK 162.5 million (56.5).

Net profit amounted to SEK 188.0 million (86.2), corresponding to earnings per share of SEK 3.70 (2.03).

Cash flow from operating activities amounted to an inflow of SEK 129.5 million (39.1).

CAPITAL MARKETS DAY 2023

The year-end report will be presented at Surgical Science's Capital Markets Day today, February 22, at 2-5.30 p.m. No other MAR-regulated information will be presented. For the agenda for the Capital Markets Day, see Surgical Science's website, under press releases.

Gothenburg, Sweden, February 22, 2023
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the clinical environment. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science has approximately 240 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and in Seattle and Cleveland, US. Through sales offices in the US and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: certifiedadviser@penser.se).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-22 07:30 CET.


230222 Q42022 ENG.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page